Charles River Laboratories International, Inc. logo
Charles River Laboratories International, Inc. (CRL)
Compare

CRL Cash Flow Statement

Operating, investing, and financing cash flow analysis

CRL Quarterly Cash Flow Statement (USD)

Quarterly ReportTTM
03/28/2026
12/27/2025
09/27/2025
06/28/2025
03/29/2025
12/31/2024
09/28/2024
06/29/2024
Cash from Operations (CFO)
607.026M41.077M147.520M213.826M204.603M171.697M159.362M251.792M193.535M
-184.650M-14.843M-276.555M54.422M52.326M25.469M-215.699M68.679M89.988M
Depreciation & Amortization
350.099M67.151M78.277M85.164M119.507M120.364M102.104M88.198M86.082M
62.697M22.381M0.0023.267M17.049M13.135M17.235M19.331M16.587M
Change in Accounts Receivable
2.696B700.251M708.856M734.482M552.340M756.629M509.404M533.884M543.332M
Change in Inventory
Change in Accounts Payable
Change in Working Capital
-93.285M-106.079M6.772M-5.145M11.167M1.287M-42.396M71.491M-11.332M
Cash from Investing
-215.736M-55.908M-88.950M-35.580M-35.298M-59.324M-75.616M-38.721M-39.486M
-403.307M-405.006M19.140M-17.441M0.0017.441M0.000.00-5.479M
Cash from Financing
Debt Repayment
-215.826M-208.285M-96K-93K-7.352M-353.132M-124K-100.786M-8.914M
0.000.000.000.000.000.000.000.000.00
391.290M-14.831M58.570M178.246M169.305M112.373M83.746M213.071M154.049M
Net Change in Cash
-33.538M-17.796M6.766M24.480M-46.988M26.158M-6.070M30.636M-157.828M

CRL Annual Cash Flow Statement (USD)

Annual Report
12/27/2025
12/28/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Cash from Operations (CFO)
737.646M734.577M683.898M619.640M760.799M546.575M480.936M441.140M
-144.338M10.297M474.624M486.226M390.982M364.304M252.019M226.373M
Depreciation & Amortization
403.312M361.741M314.124M303.870M265.540M234.924M198.095M161.779M
71.083M69.891M72.048M73.617M71.474M56.341M57.271M47.346M
Change in Accounts Receivable
708.856M509.404M552.355M548.132M642.881M617.740M514.033M472.248M
Change in Inventory
Change in Accounts Payable
Change in Working Capital
14.081M-30.329M-102.380M-152.554M42.942M-26.275M6.179M14.814M
Cash from Investing
-219.152M-232.967M-318.528M-324.733M-228.772M-166.560M-140.514M-140.054M
0.00-5.479M-194.785M-120.117M-1.170B-418.628M-515.701M-824.868M
Cash from Financing
Debt Repayment
-360.673M-119.175M-24.155M-38.651M-40.707M-23.979M-18.087M-13.846M
0.000.000.000.000.000.000.000.00
518.494M501.610M365.370M294.907M532.027M380.015M340.422M301.086M
Net Change in Cash
10.427M-78.910M43.266M-5.100M13.195M-6.927M42.728M30.987M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Wilmington, MA
18,700 employees
Healthcare / Medical - Diagnostics & Research
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
James C. Foster